DexCom (DXCM) Fell Due to Modest Guidance

Core Insights - Brown Advisory Mid-Cap Growth Strategy underperformed its benchmark, the Russell Midcap® Growth Index, which increased approximately 3% in Q3 2025 [1] Company Overview - DexCom, Inc. (NASDAQ:DXCM) is a medical device company specializing in continuous glucose monitoring (CGM) systems [2] - As of December 17, 2025, DexCom's stock closed at $65.75 per share, with a market capitalization of $26.086 billion [2] Financial Performance - For Q3 2025, DexCom reported global revenue of $1.21 billion, an increase from $994 million in Q3 2024 [4] - The one-month return of DexCom was 13.90%, but its shares lost 12.24% of their value over the last 52 weeks [2] Market Sentiment and Challenges - DexCom exceeded second quarter consensus expectations, but a modest guidance increase did not reflect year-to-date strength, impacting market sentiment [3] - A short report raised concerns about yield, accuracy, and injury rates related to the G7 launch, contributing to stock volatility [3] - Early injury rates for the G7 were higher than the G6 but have since improved and remain below those of key competitors [3] Hedge Fund Interest - At the end of Q3 2025, 71 hedge fund portfolios held DexCom, an increase from 60 in the previous quarter [4]